On January 9, 2025, Verdiva Bio Limited announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. Verdiva launched with an oversubscribed Series A financing of $411 million, co-led by General Atlantic and Forbion, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital (collectively, “the Investor Group”). Wilson Sonsini Goodrich & Rosati advised General Atlantic on IP matters related to Verdiva’s formation and Series A funding round.

Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.

The Wilson Sonsini team that advised General Atlantic on IP matters related to the formation and Series A was led by Mike Hostetler and Minyoung Shin, and included Hee Min Noh, Shu Boboila, Katrina Otrubova, Jose Martinez, Longle Ma, David Clark, Trevor Butcher, and Wendy Devine.

For more information, please see Verdiva’s press release, or related coverage by Fierce Biotech.